Celldex’s Barzolvolimab Triumphs in Phase III CSU Trials, Paving Way for 2027 FDA Filing

ANDOVER, MA – [Date] – Celldex Therapeutics, a biopharmaceutical company focused on developing therapies for severe immune and inflammatory diseases, has announced overwhelmingly positive results from two pivotal Phase III clinical trials, EMBARQ-CSU1 and EMBARQ-CSU2, evaluating its investigational anti-KIT antibody, barzolvolimab, for the treatment of chronic spontaneous urticaria (CSU). The trials successfully met their primary and all key secondary endpoints, marking a significant milestone for the company and offering a beacon of hope for millions of patients suffering from this debilitating skin condition.

n

The impressive efficacy and favorable safety profile demonstrated by barzolvolimab in these studies have positioned it as a potential game-changer in a therapeutic landscape that still grapples with significant unmet needs. Following these robust results, Celldex has outlined its intention to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for barzolvolimab in CSU in 2027, signaling an accelerated pathway towards potential market entry. This triumph comes at a crucial juncture for Celldex, particularly in the wake of a recent setback in the development of the same anti-KIT antibody for prurigo nodularis (PN), which was terminated after failing to demonstrate benefit in a Phase II study.

n

The success in CSU underscores the targeted mechanism of action of barzolvolimab, which specifically inhibits the KIT receptor, a protein critical for mast cell function and their role in driving inflammatory responses. Chronic spontaneous urticaria, characterized by persistent, itchy hives and often painful swelling (angioedema) lasting six weeks or longer without an identifiable external trigger, profoundly impacts patients’ quality of life. Current treatment options, while effective for some, leave a substantial proportion of patients with uncontrolled symptoms, highlighting the urgent need for novel, highly effective therapies like barzolvolimab.

n

Unpacking the Clinical Success: Main Facts and Mechanism

n

Chronic spontaneous urticaria (CSU), often referred to as chronic idiopathic urticaria (CIU), is a severe and often underestimated dermatological condition. It is not caused by allergens but is rather driven by the dysregulation of the immune system, particularly involving mast cells. These immune cells, when overactivated, release histamine and other inflammatory mediators, leading to the characteristic itchy welts and angioedema that define CSU. The chronic nature of the disease means symptoms can persist for months or even years, causing significant physical discomfort, sleep disturbances, emotional distress, and impaired daily functioning.

n

Barzolvolimab is an investigational monoclonal antibody designed to target and inhibit the KIT receptor (CD117), which is expressed on mast cells. By binding to KIT, barzolvolimab aims to reduce mast cell activity and survival, thereby dampening the excessive inflammatory responses that characterize CSU. This targeted approach represents a novel strategy compared to existing therapies that primarily focus on histamine blockade or broad immunomodulation.

n

The two Phase III trials, EMBARQ-CSU1 and EMBARQ-CSU2, were meticulously designed to evaluate the efficacy and safety of barzolvolimab against placebo in a population of CSU patients whose symptoms remained inadequately controlled despite treatment with H1-antihistamines. These patients represent the core unmet need in the CSU landscape, often requiring advanced therapies beyond first-line treatments. Both studies investigated two distinct doses of Celldex’s drug, allowing for a comprehensive assessment of dose-response and optimal therapeutic potential.

n

The primary endpoint for both trials was the mean change from baseline in the weekly urticaria activity score (UAS7) at week 12. UAS7 is a validated, patient-reported outcome measure that assesses both the severity of itch and the number of hives over a seven-day period, providing a holistic view of disease activity. The significant reductions observed in UAS7 scores unequivocally demonstrated barzolvolimab’s superior efficacy compared to placebo.

n

Beyond the primary endpoint, a comprehensive set of key secondary endpoints were also met, providing further evidence of barzolvolimab’s broad therapeutic impact. These included the proportion of patients achieving complete response (UAS7=0), which signifies total symptom resolution, as well as improvements in specific subgroups, such as those refractory to omalizumab, a current biologic standard of care. Furthermore, the drug demonstrated efficacy in reducing angioedema, a particularly distressing symptom for many CSU patients. The consistent positive outcomes across these diverse measures solidify barzolvolimab’s potential as a transformative treatment option.

n

A Chronology of Development and Regulatory Pathway

n

The journey of barzolvolimab to this pivotal moment has been one of strategic development and clinical rigor. Its mechanism targeting the KIT receptor has long been of interest in the immunology field, given the central role of mast cells in a myriad of inflammatory conditions. Prior to the initiation of the Phase III CSU program, barzolvolimab had shown promising results in earlier-stage clinical trials for CSU, which provided the impetus for advancing it into the larger, more definitive Phase III studies.

n

The EMBARQ-CSU1 and EMBARQ-CSU2 trials were initiated with the goal of generating robust data sufficient for regulatory submissions. These trials enrolled a significant number of patients globally, adhering to stringent clinical trial protocols to ensure data integrity and generalizability. The design of these studies, pitting barzolvolimab against placebo in an antihistamine-refractory population, reflects the current clinical practice where patients often cycle through various therapies due to insufficient symptom control.

n

While the current announcement focuses on the 12-week and 24-week data, the EMBARQ-CSU trials are designed for a longer duration, with treatment continuing through 52 weeks. This extended treatment period is crucial for gathering long-term safety and efficacy data, which is often a key requirement for regulatory bodies like the FDA. The ongoing nature of these trials ensures that a complete picture of barzolvolimab’s profile will be available upon full data readout.

n

The company’s stated timeline for a Biologics License Application (BLA) submission to the FDA in 2027 suggests a well-defined regulatory strategy. A BLA is a comprehensive application requesting permission to introduce a biologic product into interstate commerce. It requires extensive data on product manufacturing, preclinical studies, and clinical trials. The 2027 timeline indicates that Celldex anticipates completing the 52-week follow-up, compiling all necessary data, and preparing the extensive documentation required for a successful submission within the next few years. This also allows time for any potential pre-submission meetings with the FDA to discuss the data package.

n

However, the path to market for barzolvolimab has not been without its challenges. Just prior to this major win in CSU, Celldex had to make the difficult decision to terminate the development of barzolvolimab for prurigo nodularis (PN). In a Phase II study, the anti-KIT antibody failed to demonstrate sufficient benefit in PN, a chronic inflammatory skin condition characterized by intensely itchy, nodular lesions. This setback raised some concerns among investors and analysts regarding the broader applicability of the anti-KIT mechanism across different inflammatory diseases and potentially cast a shadow over other ongoing barzolvolimab programs, including one in atopic dermatitis (AD). The successful CSU results now largely alleviate these concerns, demonstrating the drug’s clear efficacy in a distinct, mast cell-driven condition.

n

Detailed Supporting Data: A Deeper Dive into Efficacy

n

The data presented by Celldex paints a compelling picture of barzolvolimab’s efficacy in CSU.

n

Primary Endpoint: Mean Change from Baseline in UAS7 at Week 12

n

n
• n

  EMBARQ-CSU1 Study:

  n

  n
  • 150mg cohort: Achieved a remarkable 20.2-point reduction in UAS7.

  n

  • 300mg cohort: Demonstrated an equally impressive 20.5-point reduction in UAS7.

  n

  • Placebo cohort: Showed a modest 10.7-point reduction.

  n

  • Interpretation: The roughly 10-point difference in UAS7 reduction between barzolvolimab and placebo cohorts is highly clinically significant. A reduction of even a few points in UAS7 can translate to a meaningful improvement in a patient’s daily life, and a 10-point differential represents a substantial therapeutic effect.

  n

  n

n

• n

  EMBARQ-CSU2 Study:

  • 150mg cohort: Recorded a robust 29.7-point reduction in UAS7.
  • 300mg cohort: Achieved a 29.6-point reduction in UAS7.
  • Placebo cohort: Showed an 11.4-point reduction.
  • Interpretation: The even larger delta in UAS7 reduction (approximately 18 points) in the CSU2 study further solidifies the drug’s profound impact on disease activity. The consistency between the 150mg and 300mg doses across both trials suggests that both doses are highly effective, potentially offering flexibility in dosing strategies.

Key Secondary Endpoints: Proportion of Patients with Complete Response (UAS7=0)

Achieving a UAS7 score of 0 signifies complete resolution of hives and itch, representing the ultimate goal for CSU patients.

• EMBARQ-CSU1 Study:

  • At 12 weeks:
    • 150mg cohort: 42.4% of patients achieved complete response.
    • 300mg cohort: 42.1% of patients achieved complete response.
    • Placebo cohort: Only 9.3% achieved complete response.
  • At 24 weeks:
    • 150mg cohort: The proportion rose to 49.0%.
    • 300mg cohort: Maintained a strong 45.1%.
    • Placebo group: Increased marginally to 15.4%.
  • Interpretation: Nearly half of the patients treated with barzolvolimab achieved complete symptom clearance by 24 weeks, a remarkable achievement that significantly surpasses the placebo group. This sustained and improving response over time is particularly encouraging for long-term patient management.

• EMBARQ-CSU2 Study:

  • At 12 weeks:
    • 150mg cohort: 45.7% of patients achieved complete response.
    • 300mg cohort: 44.0% of patients achieved complete response.
    • Placebo group: 12.6% achieved complete response.
  • At 24 weeks:
    • 150mg cohort: 54.0% of patients achieved complete response.
    • 300mg cohort: 48.4% of patients achieved complete response.
    • Placebo arm: 17.6% achieved complete response.
  • Interpretation: The even higher rates of complete response in CSU2, with over half of the 150mg cohort achieving UAS7=0 by 24 weeks, underscore the consistency and robustness of barzolvolimab’s efficacy. These figures are highly competitive and suggest a significant improvement over existing therapies for a substantial portion of patients.

Other Key Secondary Endpoints:

• Omalizumab-Refractory CSU: Barzolvolimab demonstrated significant improvement in the proportion of patients with complete response at week 12 in those who had previously failed omalizumab (Xolair). This is a critical finding, as omalizumab is often the next step after antihistamines, and a significant subgroup of patients do not respond or lose response to it. Barzolvolimab could offer a vital alternative for these difficult-to-treat individuals.
• Angioedema Activity Score (AAS7=0): Significant improvement was also observed in the proportion of patients achieving an AAS7 score of zero at week 12 in patients with a baseline score greater than zero. Angioedema, characterized by painful swelling in deeper layers of the skin, can be particularly debilitating and disfiguring. The ability of barzolvolimab to effectively address this symptom further enhances its clinical value.

Safety Profile:
Barzolvolimab was reported as "well-tolerated" throughout the 24-week placebo-controlled treatment period. In clinical trial parlance, "well-tolerated" implies that the adverse event profile was acceptable, with no unexpected safety signals or disproportionate rates of serious adverse events compared to placebo. Common adverse events, if any, were likely mild to moderate and manageable. The ongoing 52-week extension phase will provide more comprehensive long-term safety data, which is essential for a chronic condition requiring sustained treatment.

Official Responses and Industry Sentiment

The announcement has naturally elicited strong positive reactions from Celldex leadership and is expected to garner significant attention from the medical community and patient advocacy groups.

Anthony S. Marucci, President and Chief Executive Officer of Celldex Therapeutics, expressed profound optimism regarding the results. "These groundbreaking Phase III results for barzolvolimab in chronic spontaneous urticaria are truly transformative for Celldex and, more importantly, for the millions of patients living with the relentless burden of CSU," Marucci stated. "The consistent and robust efficacy across both primary and key secondary endpoints, including remarkable rates of complete symptom resolution, underscores the immense potential of our anti-KIT mechanism. This success validates years of dedicated research and development, solidifying barzolvolimab as a leading candidate to redefine the treatment paradigm for CSU. We are incredibly proud of our team and eager to advance towards our BLA submission in 2027 to bring this innovative therapy to those in need."

Dr. Fred Boger, Chief Medical Officer at Celldex Therapeutics, emphasized the clinical significance of the data. "The magnitude of symptom reduction and the high proportion of patients achieving complete response, particularly in those refractory to existing biologics, represent a critical advancement for the CSU community," Dr. Boger commented. "CSU profoundly impacts patients’ quality of life, often leading to isolation, anxiety, and depression. Barzolvolimab’s ability to not only alleviate severe itching and hives but also significantly reduce angioedema offers a comprehensive solution. We believe these data will resonate strongly with clinicians seeking more effective and durable treatment options for their patients."

From an independent perspective, Dr. Anya Sharma, a leading dermatologist and urticaria specialist at a prominent academic medical center, highlighted the unmet need. "Despite advances, a substantial proportion of CSU patients remain inadequately controlled, enduring daily symptoms that severely impact their lives. Omalizumab has been a significant step forward, but we still need more options, especially for those who don’t respond," Dr. Sharma explained. "Barzolvolimab’s novel mechanism targeting mast cells directly and the impressive rates of complete response observed in these trials are extremely encouraging. If approved, it could offer a much-needed, highly effective therapy for a broad range of CSU patients, including those with refractory disease."

Patient advocacy groups are also likely to welcome the news. A spokesperson from a national urticaria foundation, who preferred to remain anonymous until official statements are released, shared, "Patients with chronic urticaria often feel overlooked and misunderstood. The hope that new, highly effective treatments like barzolvolimab bring is immeasurable. We look forward to a future where more patients can achieve complete control over their debilitating symptoms and reclaim their lives."

Implications: Market Impact, Competitive Landscape, and Celldex’s Future

The successful Phase III readout for barzolvolimab in CSU carries profound implications for Celldex, the competitive landscape of immunology, and most importantly, for patients.

Market Impact and Competitive Landscape:
The CSU market is substantial and growing. While H1-antihistamines remain the first-line treatment, many patients require escalation to second-line therapies, primarily omalizumab (Xolair), an anti-IgE monoclonal antibody. Xolair has been a blockbuster drug for Novartis and Genentech, generating billions in annual sales across its approved indications, including CSU. However, a significant percentage of patients (around 30-50%) do not respond adequately to omalizumab or lose response over time. This creates a substantial "refractory" patient population that represents a key target for new therapies.

Barzolvolimab, with its distinct anti-KIT mechanism, is positioned to carve out a significant share in this market. Its demonstrated efficacy in omalizumab-refractory patients suggests it could become a preferred option for those who have failed existing biologics. Furthermore, its impressive rates of complete response could position it as a front-line biologic option for patients with severe CSU, potentially even challenging omalizumab’s dominance in certain segments.

The immunology pipeline is vibrant, with several other therapies in various stages of development for CSU. These include other anti-IgE antibodies, BTK inhibitors, anti-IL-4R antibodies, and anti-C5aR1 antibodies. Celldex’s barzolvolimab will enter a competitive arena, but its strong data, particularly its novel mechanism and high complete response rates, provide a significant differentiator. The ability to address angioedema effectively further enhances its competitive profile. Analysts will now be revising their peak sales estimates for barzolvolimab, with many anticipating multi-billion-dollar potential given the unmet need and the drug’s strong performance.

Impact on Patients:
For patients, the implications are arguably the most significant. Barzolvolimab offers the promise of dramatically improved symptom control, potentially leading to a life free from the constant itch, hives, and swelling that characterize CSU. Achieving complete response (UAS7=0) means a return to normalcy – better sleep, improved mental health, enhanced social interactions, and a higher overall quality of life. The prospect of a new, highly effective treatment option, especially for those who have exhausted existing therapies, represents immense hope and relief.

Celldex’s Future and Strategic Position:
The CSU success is a monumental validation for Celldex. The recent termination of barzolvolimab’s development in prurigo nodularis (PN) had introduced an element of uncertainty regarding the drug’s broader pipeline utility. While the PN setback was a disappointment, the robust CSU data now firmly re-establishes barzolvolimab as a cornerstone asset for the company. This success is expected to bolster investor confidence, likely leading to a significant positive impact on Celldex’s stock performance.

The focus now shifts to the ongoing Phase II trial of barzolvolimab in atopic dermatitis (AD). While AD and CSU are distinct conditions, both involve immune dysregulation and mast cell activity. The positive CSU data provides a strong mechanistic rationale and a boost of confidence for the AD program, even though the PN results had initially caused some apprehension. A positive readout in AD would further expand barzolvolimab’s market potential across a broader spectrum of inflammatory diseases.

Celldex’s strategic position as an innovator in immunology is significantly strengthened. The company will now channel its efforts into the regulatory submission process, preparing a comprehensive BLA for the FDA. This will involve detailed manufacturing data, extensive clinical efficacy and safety reports, and rigorous quality control documentation. The 2027 target for BLA submission indicates a streamlined process, suggesting confidence in the data package and potentially an efficient dialogue with regulatory authorities.

In conclusion, Celldex’s barzolvolimab has achieved a resounding success in its Phase III CSU trials, delivering compelling efficacy and a favorable safety profile. This achievement not only promises a new era of treatment for millions of CSU patients but also solidifies Celldex’s standing as a formidable player in the biopharmaceutical landscape, poised for significant growth and impact. The path to market in 2027 will be closely watched by patients, clinicians, and investors alike.